Marker Therapeutics
MRKR
6 hedge funds and large institutions have $163K invested in Marker Therapeutics in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
37% more capital invested
Capital invested by funds: $119K → $163K (+$44K)
20% more funds holding
Funds holding: 5 → 6 (+1)
0.01% more ownership
Funds ownership: 0.04% → 0.04% (+0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$53.9K |
| 2 |
Goldman Sachs
New York
|
+$47.1K |
| 3 |
NSIM
North Star Investment Management
Chicago,
Illinois
|
+$9.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$60.4K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $54K | +$53.9K | +1,211 | New |
|
|
2
Millennium Management
New York
| $50K | -$60.4K | -1,358 | -55% |
|
|
3
Goldman Sachs
New York
| $48K | +$47.1K | +1,059 | New |
|
|
NSIM
4
North Star Investment Management
Chicago,
Illinois
| $10K | +$9.92K | +223 | New |
|
|
AG
5
Advisor Group
Phoenix,
Arizona
| $1K | – | – | – |
|
|
PAM
6
Panagora Asset Management
Boston,
Massachusetts
| – | -$23K | -678 | Closed |
|
MRKR Hedge Fund Activity: Q1 2017 in Review
6 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2017, worth a combined $163K — up 37% from $119K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MRKR positions and 2 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $53.9K. The largest seller was Millennium Management, cutting an estimated $60.4K.
- 6 institutional investors held Marker Therapeutics (MRKR) as of Q1 2017, up from 5 in Q4 2016.
- Funds reported $163K of Marker Therapeutics stock for Q1 2017, up 37% quarter-over-quarter.
- 3 funds opened new Marker Therapeutics positions in Q1 2017 and 2 closed out, a net change of +1 holder.
- The largest Marker Therapeutics buyer in Q1 2017 was Virtu KCG Holdings, an estimated $53.9K added.
- The largest Marker Therapeutics seller in Q1 2017 was Millennium Management, an estimated $60.4K sold.
Based on aggregated 13F filings for Q1 2017.